펩타이드 및 올리고뉴클레오티드 CDMO 시장 : 시장 규모, 점유율 및 동향 분석 보고서 - 제품별, 서비스별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Peptide and Oligonucleotide CDMO Market Summary

The global peptide and oligonucleotide CDMO market size was valued at USD 2.80 billion in 2024 and is projected to reach USD 8.14 billion by 2033, growing at a CAGR of 12.75% from 2025 to 2033. The market is driven due to increasing demand for complex and targeted therapeutics, growing investment in biologics and nucleic acid-based drug development, rising outsourcing trends among pharmaceutical and biopharmaceutical companies, and advancements in synthesis and delivery technologies for peptides and oligonucleotides.

In addition, oligonucleotides and peptides have shown potential in treating a wide range of ailments, including metabolic disorders, cancer, and genetic diseases. Innovations in peptide synthesis, synthetic chemistry, and oligonucleotide manufacturing have made it easier to produce and design complex molecules. This has substantially increased the applications of peptides and oligonucleotides in therapeutic usage and thus boosted the demand for contract development and manufacturing organizations (CDMOs) with specialized proficiency in these areas.

Furthermore, the rising trend toward personalized medicine has driven the need for customized peptide and oligonucleotide therapies, thereby supporting the demand for CDMOs that are vital in the production and development of these personalized treatment therapies. Moreover, regulatory bodies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have diligently worked on establishing guidelines for the manufacturing and development of oligonucleotides and peptides. Hence, the aforementioned factors are responsible for the lucrative growth of the market.

Global Peptide And Oligonucleotide CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global peptide and oligonucleotide CDMO market report based on product, service, end use, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Peptides
• Oligonucleotides
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Contract Development
• Contract Manufacturing
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical Companies
• Biopharmaceutical Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Norway
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Value chain based analysis (Model 2)
  • 1.7.3. Multivariate Analysis (Model 3)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Landscape Insights

Chapter 3. Peptide and Oligonucleotide CDMO Market: Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Peptide and Oligonucleotide CDMO Market Dynamics
  • 3.2.1. Market Driver Impact Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Market Opportunities
• 3.3. Technological Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Supply Chain Analysis
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Forces Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Peptide and Oligonucleotide CDMO Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Peptide and Oligonucleotide CDMO Market Product Movement Analysis
• 4.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Peptides
  • 4.4.1. Peptides Market Estimates and Forecasts, 2021 - 2033 (USD million)
• 4.5. Oligonucleotides
  • 4.5.1. Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Peptide and Oligonucleotide CDMO Market: Service Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Peptide and Oligonucleotide CDMO Market Service Movement Analysis
• 5.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
• 5.4. Contract Development
  • 5.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Contract Manufacturing
  • 5.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Peptide and Oligonucleotide CDMO Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Peptide and Oligonucleotide CDMO Market End Use Movement Analysis
• 6.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Pharmaceutical Companies
  • 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Biopharmaceutical Companies
  • 6.5.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Peptide and Oligonucleotide CDMO Market: Regional Estimates & Trend Analysis by Product, Service, End Use

• 7.1. Regional Market Dashboard
• 7.2. Global Regional Market Snapshot
• 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.6. Oman
    • 7.8.6.1. Key Country Dynamics
    • 7.8.6.2. Competitive Scenario
    • 7.8.6.3. Regulatory Framework
    • 7.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.7. Qatar
    • 7.8.7.1. Key Country Dynamics
    • 7.8.7.2. Competitive Scenario
    • 7.8.7.3. Regulatory Framework
    • 7.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
  • 8.1.1. Market Leaders
  • 8.1.2. Emerging Players
• 8.2. Peptide and Oligonucleotide CDMO Market Share Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. PolyPeptide Group
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Product/Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. STA Pharmaceutical Co. Ltd.
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Product/Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Bachem
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Product/Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Creative Peptides
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Product/Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Aurigene Pharmaceutical Services Ltd.
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Product/Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Merck KGaA
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Product/Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. EUROAPI
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Product/Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Curia Global, Inc.
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Product/Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. CordenPharma
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Product/Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Sylentis, S.A.
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Product/Service Benchmarking
    • 8.3.10.4. Strategic Initiatives